CPA
TELO icon

Capital Performance Advisors’s Telomir Pharmaceuticals TELO Stock Holding History

Capital Performance Advisors’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22
Closed -$141 – 2785
2024
Q3 		$141 Buy
+22
New +$107 ﹤0.01% 2636

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Performance Advisors's TELO Position: Q4 2024 in Review

Capital Performance Advisors sold out of Telomir Pharmaceuticals (TELO) in Q4 2024, closing a stake of 22 shares — an estimated $141 sold.

Capital Performance Advisors first reported a position in TELO in Q3 2024 and held it in 1 quarter. The position peaked at $141 in Q3 2024. 39 funds tracked by Wall St. Rank hold TELO as of Q4 2024.

  • Capital Performance Advisors reported no remaining Telomir Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 22 Telomir Pharmaceuticals shares in Q4 2024, an estimated $141.
  • Capital Performance Advisors first reported a position in Telomir Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Telomir Pharmaceuticals position peaked at $141 in Q3 2024.
  • 39 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.